TIBET PHARMA(SH:600211)2022-03-11 16:00Financial Performance - The company's operating revenue for 2021 was approximately ¥2.14 billion, representing a 55.75% increase compared to ¥1.37 billion in 2020[21]. - The net profit attributable to shareholders for 2021 was approximately ¥208.94 million, a decrease of 50.03% from ¥418.10 million in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥66.69 million, down 81.74% from ¥365.33 million in 2020[21]. - The basic earnings per share for 2021 was ¥0.84, a decline of 50.30% compared to ¥1.69 in 2020[22]. - The total assets of the company at the end of 2021 were approximately ¥3.80 billion, an increase of 29.15% from ¥2.94 billion at the end of 2020[21]. - The net cash flow from operating activities for 2021 was approximately ¥366.53 million, a decrease of 14.39% from ¥428.17 million in 2020[21]. - The company's net assets attributable to shareholders at the end of 2021 were approximately ¥2.63 billion, a slight increase of 2.11% from ¥2.58 billion at the end of 2020[21]. - The company reported a weighted average return on equity of 8.09%, a decrease of 7 percentage points[25]. - The weighted average return on equity after deducting non-recurring gains and losses was 2.58%, down 10.60 percentage points[25]. Product Sales and Market Performance - Sales of the new product "New Vitality" reached 4.59 million units, with sales revenue increasing by 75.57% compared to the previous year[33]. - Sales of the main product, Xinhuisu, reached 4.59 million units with revenue of 1.68 billion yuan, a year-on-year increase of 75.57%; IMDUR sales revenue was 301.65 million yuan, up 8.31%[37]. - The main business income from cardiovascular products, including Xinhuisu, Yimuduo, and Nuodikan, accounted for 95.85% of total revenue, with Xinhuisu alone contributing 79.16% and growing by 75.57% compared to the previous year[50]. - The company launched a new product, Nuodikan granules, in 2021, which offers higher absorption and bioavailability compared to the capsule form[49]. - The company’s domestic revenue was 1,928.56 million RMB, with a year-on-year growth of 64.54%[60]. - The company’s revenue from external use products was CNY 5,051.21 million, with a gross margin of 72.16%, and a year-on-year revenue increase of 2.06%[90]. Research and Development - The company has invested significantly in high-tech biopharmaceutical products and formed strategic partnerships to expand its product portfolio, including in the medical device and COVID-19 vaccine sectors[49]. - The company is conducting research on artificial cultivation of Rhodiola rosea, achieving a significant increase in seedling survival rates and meeting pharmacopoeia requirements for active ingredient content[40]. - The company has initiated a clinical trial for the recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) eye drops, which showed good safety but requires further exploration of efficacy, leading to a temporary halt in development[91]. - The company’s R&D investment amounted to 6,011.07 million RMB, representing 4.93% of operating revenue and 3.28% of net assets, with a capitalization ratio of 0%[99]. - The R&D investment for the rhIL-1Ra eye drops project was 74.65 million RMB, which is a 64.48% decrease compared to the same period last year[101]. Operational and Strategic Initiatives - The company is preparing for the market launch of the high-pressure balloon dilation catheter, which has obtained the necessary medical device registration certificates[36]. - The company has established a new production base in Lhasa, which received its drug production license on February 15, 2022, enhancing production capacity to meet market demand[41]. - The company has paused further development of the rhIL-1Ra eye drop project after initial clinical trials showed good safety but uncertain efficacy[40]. - The company has implemented electronic management of marketing channels for real-time data control and has established an expert system for academic promotion to enhance product marketing[37]. - The company is focusing on digital transformation and plans to establish a data center for business data visualization[118]. Financial Management and Governance - The company emphasizes the importance of maintaining independent operations from its controlling shareholder, ensuring compliance with legal and regulatory requirements[125]. - The company conducted four shareholder meetings during the reporting period, ensuring compliance with legal procedures and protecting the rights of all shareholders, particularly minority shareholders[125]. - The company has not experienced any new instances of fund occupation by major shareholders or related parties during the reporting period, maintaining financial integrity[125]. - The company has a structured process for determining the remuneration of its directors and senior management[139]. - The company has maintained a focus on compliance and governance with the appointment of new independent directors[136]. Environmental and Social Responsibility - The company has maintained compliance with national environmental standards, with no pollution incidents or penalties reported for several years[187]. - The company has established an emergency response plan for environmental incidents, which has been filed with the ecological environment department, with filing number 510104-2021-L-1[172]. - The company has participated in the "Ten Thousand Enterprises Helping Ten Thousand Villages" initiative for the third time, donating funds and medicines[188]. - The "Tibetan Medicine Modernization Comprehensive Technology Industrial Park" project has provided nearly 100 job opportunities for local farmers[188]. - The company has integrated social responsibility into its development strategy, focusing on sustainable growth and community support[4].